TELOMERASE CATALYTIC SUBUNIT mRNA IN LARYNGEAL SQUAMOUS CELL CARCINOMAS
Abstract
Background. Re-activation of the enzyme telomerase, has been detected in nearly 90% of human malignancies. In contrast, normal human somatic cells, with the exception of germ cells and stem cells of renewable tissues, do not have detectable telomerase activity. Transcription of human telomerase catalytic subunit (hTERT) gene represents a ratelimiting step for telomerase activity, a key enzyme implicated in cellular immortalisation and transformation. The aim of our study was to explore the hypothesis that quantitative differences exist in the level of hTERT mRNA expression between laryngeal squamous cell carcinomas (LC) and the surrounding normal or reactive hyperplastic laryngeal mucosa, in order to obtain insights into the role of telomerase re-activation in the multistep process of laryngeal carcinogenesis.
Methods. We tested 45 LC and 45 normal or reactive hyperplastic laryngeal epithelia (control tissue) from the same patients for the presence of human telomerase catalytic subunit (hTERT) mRNA by using Roche LightCycler Telo TAGGG hTERT Quantification kit. The hTERT index was calculated to express the relative quantity levels of hTERT mRNA.
Results. hTERT mRNA was detectable in 12 of 45 (27%) control laryngeal epithelia and 37 of 45 LC (82%); 3 of 5 grade 1 (60%), 14 of 19 grade 2 (74%) and 20 of 21 grade 3 (95%) LC. The mean hTERT indices were 0.10 for control laryngeal tissue, 0.68 for grade I, 2.16 for grade II and 2.56 for grade III LC. The differences between hTERT indices in the control laryngeal epithelia and LC are statistically significant (p < 0.05). Although progressive increase of mean hTERT indices was observed with increasing histological grade of LC, the differences did not reach statistical significance.
Conclusions. We believe that low relative quantities of hTERT mRNA found occasionally in normal and reactive hyperplastic laryngeal epithelium originate from the stem cells and correspond to a self-renewal capacity of the squamous epithelium. However, higher relative quantities of hTERT mRNA in the majority of LC are the consequence of telomerase reactivation in the multistep process of laryngeal carcinogenesis, reflecting the appearance of immortal cell population(s).
Downloads
References
Dong Y, Sui L, Tai Y, Sugimoto K, Hirao T, Tokuda M. Prognostic significance of cyclin E overexpression in laryngeal squamous cell carcinomas. Clin Cancer Res 2000; 6: 4253–8.
Pompe-Kirn V, Golouh R, Lindtner J, Primic-Žakelj M, Ravnihar B, Rudolf Z, Zakotnik B, eds. Incidenca raka v Sloveniji 1998. Ljubljana: Onkološki inštitut, 2001.
Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996; 46: 5–27.
Rowley H. The molecular genetics of head and neck cancer. J Laryngol Otol 1998; 112: 607–12.
Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993; 7: 139–46.
Blackburn EH. Structure and function of telomeres: Nature 1991; 350: 569–73.
Rudolph P, Schubert C, Tamm S et al. Telomerase activity in melanocytic lesions. A potential marker of tumor biology. Am J Pathol 2000; 156: 1425–32.
Hohaus S, Cavallo S, Bellacosa A et al. Telomerase activity in human laryngeal squamous cell carcinomas. Clin Cancer Res 1996; 2: 1859–900.
Curran AJ, Gullane PJ, Irish J, Macmillan C, Freeman J, Kamel-Reid S. Telomerase activity is upregulated in laryngeal squamous cell carcinoma. Laryngoscope 2000; 110: 391–6.
Dhaene K, Van Marck E, Parwaresch R. Telomeres, telomerase and cancer: an up-date. Virchows Arch 2000; 437: 1–16.
De Kok JB, Schalken JA, Aalders TW, Reurs TJM, Willems HL, Swinkels DW. Quantitative measurement of telomerase reverse trascriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer 2000; 87: 217–20.
Hellquist H, Cardesa A, Gale N, Kambič V, Michaels L. Criteria for grading in the Ljubljana classification of epithelial hyperplastic laryngeal lesions. A study by members of the working group on epithelial hyperplastic laryngeal lesions of the European Society of Pathology. Histopathology 1999; 34: 226–33.
Gale N, Kambič V, Michaels L, Cardesa A, Hellquist H, Zidar N, Poljak N. The Ljubljana classification: a practical strategy for the diagnosis of laryngeal precancerous lesions. Adv Anat Pathol 2000; 7: 240–51.
Luzar B, Gale N, Klopčič U, Fischinger J. Laryngeal granuloma: characteristics of the covering epithelium. J Laryngol Otol 2000; 114: 264–7.
Sobin LH, Wittekid C eds. TNM classification of malignant tumours. International Union Against Cancer (UICC), 5th edn. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley-Liss, 1997.
Roche Molecular Biochemicals. Light Cycler TeloTAGGG hTERT quantification kit. The fastest way to telomerase quantification. Biochemica 2000; 2: 12–3.
Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503–14.
Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymatic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973; 41: 181–90.
Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996; 8: 66–71.
Meyerson M, Counter CM, Eaton EN et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 785–95.
De Kok JB, Schalken JA, Aalders TW, Reurs TJM, Willems HL, Swinkels DW. Quantitative measurement of telomerase reverse trascriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer 2000; 87: 217–20.
Kyo S, Kanaya T, Takakura M, Tanaka M, Inoue M. Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 1999; 80: 60–3.
Fujimoto R, Kamata N, Yokoyama K, Ueda N, Satomura K, Hayashi E, Nagayama M. Expression of telomerase components in oral keratiocytes and squamous cell carcinomas. Oral Oncol 2001; 37: 132–40.
Kolquist KA, Ellisen LW, Counter CM et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998; 19: 182–6.
Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ, Weng N-P. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci USA 1999; 96: 5147–52.
Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomerase maintenance by recombination in human cells. Nat Genet 2000; 26: 447–50.
Luzar B, Poljak M, Marin IJ, Fischinger J, Gale N. Quantitative measurement of telomerase catalytic subunit (hTERT) mRNA in laryngeal squamous cell carcinomas. Anticancer Res 2001; 21: 4011–5.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
